Indoco Remedies Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr
The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery. Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant.
From Indoco Remedies's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹226
Market Cap
₹2.0K Cr
How does Indoco Remedies rank in Pharmaceuticals & Biotechnology?
Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Indoco Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹-24 Cr.
Full financials →📊 Revenue & Sales Performance
- →The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery.
- →Europe business is expected to drive growth with an anticipated margin of close to 15% starting FY '26.
- →US business recovery is delayed due to FDA remediation; scale-up expected once compliance issues resolve.
- →Domestic business shows steady growth with top brands like Cyclopam growing over 20% in prescriptions.
- →New product launches and strategic partnerships (e.g., with Clarity Pharma UK for 18 SKUs over 18 months) support revenue growth.
- →Semi-regulated markets expected to perform better with efforts to smoothen distributor order patterns.
- →Overall, sales growth expected to return with normalization post remediation and capacity ramp-up, likely from FY '26 onwards.
📈 Profitability & Margins
- →Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant.
- →EBITDA margins outlook:
- → - This year averaging ~10.5-11% due to challenges; previous year was ~13%.
- → - Recovery to ~13% EBITDA margins possible by Q3 FY '26 with gradual ramp-up.
- →The India domestic business and international non-US geographies are expected to recover and grow steadily from FY '26 onwards.
- →International formulations order book stands strong at INR180 crores, indicating demand.
- →Cost control measures and master manufacturing plan aim to improve operational efficiency and reduce fixed costs over time.
- →Capex investments and digital/SAP improvements are expected to enhance productivity and margins in the medium term.
- →Chronic portfolio contribution may inch up but with ongoing aggressive growth in other segments.
- →No specific earnings per share (EPS) guidance disclosed currently.
🏗️ Capital Expenditure Plans
- →Indoco Remedies has undertaken significant capex of around INR 400 crores in the past 2 years, mainly for refurbishment and capacity expansion.
- →Key investments include:
- → - Setting up a new unit at Auric for manufacturing cosmetic toothpaste (OTC toothpaste).
- → - Capacity increase for API production beyond the old site at Patalganga.
- → - Upgrading equipment to improve efficiency at the solid oral manufacturing site.
- →In the current year, about INR 200 crores has been incurred, covering new machines, upgrades, refurbishment, and some advances.
- →Equipment upgrades are aligned with digital initiatives to enable data collection and AI/ML applications for predictive quality and efficiency improvements.
- →Refurbishments at the sterile plant involve repairs and maintenance rather than complete line replacements.
- →Future capex is planned but details on quantum or timelines are under evaluation, especially linked to remediation and capacity ramp-up.
💰 Fundraising & Capital Structure
- →No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company focused on dealing with remediation, operational challenges, and cost control measures.
- →Capex for refurbishment and new capacity was funded through internal resources; INR400+ crores spent in the past 2 years.
- →No guidance or statement was given regarding raising fresh equity or debt funding in the near future.
- →The management emphasized operational efficiency, digitization, and ramp-up post regulatory challenges rather than external fundraising.
📋 Order Book & Pipeline
- →The current order book for the international formulations business to Europe and the US stands at approximately INR 180 crores.
- →This order book reflects the demand side strength despite supply-side challenges.
- →The company has faced a significant sales drop in the regulated markets due to remediation and supply disruptions but holds this order backlog as a positive indicator.
- →There is an expectation of recovery in supply and a return to earlier performance levels in markets outside the US starting from FY '26 onwards.
- →The supply challenges have led to a temporary loss of revenue, with an example of INR 90-100 crores of sales lost in one quarter alone due to these delays.
- →Overall, the order book suggests healthy demand and potential for ramp-up once compliance and production issues are resolved.
Key Metrics
Frequently Asked Questions
What were Indoco Remedies Q3 FY25 results?
The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery. Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
Indoco Remedies has undertaken significant capex of around INR 400 crores in the past 2 years, mainly for refurbishment and capacity expansion.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.